Loading clinical trials...
Loading clinical trials...
Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection
Conditions
Interventions
Voxilaprevir
Placebo to match voxilaprevir
+1 more
Locations
11
United States
Costa Mesa, California, United States
DeLand, Florida, United States
Orlando, Florida, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
Berlin, New Jersey, United States
Start Date
June 13, 2014
Primary Completion Date
December 22, 2014
Completion Date
September 28, 2015
Last Updated
September 17, 2020
NCT06718530
NCT05361603
NCT05975216
NCT05071261
NCT05906459
NCT04980157
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions